Primary Objectives:
To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer [18F]Fluciclovine and 18F-FDG PET. Secondary Objectives:
To compare uptake measures of 18F-Fluciclovine and 18F-FDG and MRI quantification of glutamate and lactate levels to tumor tissue laboratory assays (RNA seq and proteomics) of glutamine/glutamate, glucose, and lactate metabolism. To perform metabolic phenotyping of treatment naïve and recurrent GBM by advanced MRI methods at 7 Tesla The overall quality of the generated images will be evaluated. Uptake at the tumor sites will be analyzed both qualitatively and quantitatively to evaluate the activity of this radiotracer. A number of analysis methods may be tested to identify the optimal method for analyses for future studies with this radiotracer. Based on breast cancer imaging data, we suspect 18F-Fluciclovine PET uptake reflects glutamine pool size and can be estimated by the distribution volume 18F-Fluciclovine PET. Analysis of dynamic PET imaging, through both graphical and compartmental approaches, will enable estimation of radiotracer distribution volume. Compartmental kinetic analysis will also yield other estimated rate constants (K1, k2, k3, flux) which can also be evaluated. Subjects will be asked permission to access their medical records for follow-up of their clinical care and surgery outcomes as part of the consent for this study. In addition, data with regard to original diagnosis, pathology, current medications, and prior radiation and treatment history will be collected from the medical record.
